Search results
Results From The WOW.Com Content Network
As part of the deal Celgene will pay Juno $150 million and acquire 9.1 million new Juno shares (valued at $93, existing Juno shares rose 26% to $58.38). Celgene will gain the right to sell Juno's therapies around the world. This partnership surpasses the previous highest record when Pfizer agreed to a deal with Merck KGaA in 2014. [10]
The following table lists the largest biotechnology and pharmaceutical companies ranked by market capitalization in billion US dollars. The change column indicates the company's relative position in this list compared to their relative position in the preceding year; i.e., an increase would be moving closer to rank 1 and vice versa.
Meanwhile, the pharma stock is priced at a discount. Pfizer's shares trade at only 10.6 times forward earnings. That's much lower than the S&P 500 healthcare sector's forward-earnings multiple of ...
The S&P 500 is a stock market index maintained by S&P Dow Jones Indices. It comprises 503 common stocks which are issued by 500 large-cap companies traded on the American stock exchanges (including the 30 companies that compose the Dow Jones Industrial Average). The index includes about 80 percent of the American market by capitalization.
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Vertex Pharmaceuticals wasn’t one of them. The 10 stocks that ...
For premium support please call: 800-290-4726 more ways to reach us
In January 2012, Celgene agreed to acquire Avila Therapeutics, Inc., a privately held biotechnology company for $925 million, with $350 million in cash. [14] Citing a market capitalization of US$67 billion, and stock appreciation of 107%, Celgene was Forbes Magazine's number 2 ranked drug company of 2013. [15]
For premium support please call: 800-290-4726 more ways to reach us